Fubotv earnings beat by $0.10, revenue topped estimates
MIAMI - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a $57 million market cap biotechnology company, announced Thursday that its lead compound Telomir-1 inhibits three important histone demethylase enzymes that regulate gene expression, according to new preclinical data from studies conducted with Eurofins Discovery.
The data revealed that Telomir-1 blocks JMJD3, FBXL10, and FBXL11 enzymes, which are involved in tumor progression, immune response, metabolic function, and neuroinflammation. These enzymes have been difficult to target with drugs until now.
"This may be one of the most important mechanistic discoveries in Telomir-1’s development," said Erez Aminov, CEO of Telomir, in a press release statement. According to InvestingPro data, the company faces near-term financial challenges with short-term obligations exceeding liquid assets and no profitability over the last twelve months.
The findings suggest potential applications for Telomir-1 across multiple therapeutic areas. In cancer, the compound may reactivate tumor suppressor genes and silence cancer-driving genes. For inflammatory and autoimmune disorders, it could reduce overactive immune responses. The drug candidate might also address neurodegeneration and metabolic dysfunction by influencing related gene networks.
Previous studies showed that Telomir-1 reversed epigenetic gene silencing in aggressive prostate cancer models, outperforming both Paclitaxel and Rapamycin in reactivating the tumor suppressor gene STAT1.
Telomir Pharmaceuticals is continuing preclinical development of Telomir-1 across oncology and other indications, with plans to finalize its first IND-enabling program. The company focuses on developing therapies targeting underlying mechanisms of aging and age-related diseases.
The preclinical-stage biotechnology company trades on the Nasdaq under the ticker TELO. The stock currently trades at $1.84, down nearly 58% over the past six months, though showing recent momentum with strong returns over the last month. InvestingPro subscribers have access to 7 additional key insights about TELO’s financial health and growth prospects.
In other recent news, Telomir Pharmaceuticals has announced promising preclinical results for its lead compound, Telomir-1, in various studies. The compound showed potential in restoring mitochondrial function in cells from a patient with Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic disorder. This study, conducted in collaboration with Smart Assays Biotechnologies Ltd., demonstrated that Telomir-1 could restore energy in diseased cells without causing oxidative stress or cell proliferation. Furthermore, Telomir Pharmaceuticals reported that Telomir-1 outperformed established cancer treatments in restoring tumor suppressor gene function in aggressive human prostate cancer cells. The compound fully reversed hypermethylation of STAT1, a master regulator of immune surveillance, in a dose-dependent manner during a 21-day oral administration in a mouse model. Compared to established drugs like Paclitaxel and Rapamycin, Telomir-1 achieved a complete reversal of this hypermethylation, while the other drugs showed limited effects. These developments highlight the potential of Telomir-1 in treating both progeria and cancer, offering new avenues for therapeutic intervention.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.